Anne-Marie Charpentier

Subsequent Neoplasm Risico After Modern Mediastinal Radiotherapie for Pediatric Hodgkin Lymphoma: Insights From a Multi-Institutional Children’s Oncology Group Trial

Multimodality Artificial Intelligence for Involved-Site Radiotherapie: Clinical Target Volume Delineation in High-Risico Pediatric Hodgkin Lymphoma

BV plus chemotherapie bij pediatrisch hoogrisico hodgkinlymfoom: AHOD1331 fase III